Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08WYM
|
||||
| Former ID |
DAP001051
|
||||
| Drug Name |
Nafarelin
|
||||
| Synonyms |
Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Endometriosis [ICD9: 617; ICD10:N80] | Approved | [1], [2] | ||
| Therapeutic Class |
Fertility Agents
|
||||
| Company |
Pfizer Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C66H83N17O13
|
||||
| CAS Number |
CAS 76932-56-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
H01CA02
|
||||
| SuperDrug CAS ID |
cas=076932564
|
||||
| Target and Pathway | |||||
| Target(s) | Gonadotropin-releasing hormone receptor | Target Info | Agonist | [3] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| GnRH signaling pathway | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Hormone ligand-binding receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3902). | ||||
| REF 3 | Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin as a removable implant "Gonazon"; a preclinical trial. Theriogenology. 2009 Apr 15;71(7):1037-45. Epub 2009 Feb 23. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.